Literature DB >> 16142881

Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis.

Enrico Felici1, Cristina Novarini, Silvia Magni-Manzoni, Angela Pistorio, Alessandra Magnani, Elena Bozzola, Antonella Buoncompagni, Alberto Martini, Angelo Ravelli.   

Abstract

OBJECTIVE: To describe the patterns and time course of arthritis in patients with antinuclear antibody (ANA)-positive juvenile idiopathic arthritis (JIA).
METHODS: We identified patients followed during a 16-year period who had JIA by ILAR criteria, were ANA-positive (i.e., had >or= 2 positive ANA test results at titer >or= 1:160), and had a disease duration >or= 2 years. Demographic and clinical features, including ILAR category and cumulative number and type of joints affected over time, were recorded.
RESULTS: A total of 195 patients were studied. The ILAR category was oligoarthritis in 159 patients and rheumatoid factor-negative polyarthritis in 36 patients. The cumulative rate of polyarticular extension in patients with oligoarticular onset was 26%, 38%, 45%, 49%, and 51% at 1, 2, 3, 4, and 5 years, respectively. At disease onset, most patients had monoarthritis and 95% had <or= 4 joints affected. The knee was the most frequently involved of all joints, followed by the ankle and proximal interphalangeal joints. Among patients with oligoarticular onset, the presence of ankle (in case of monoarticular disease) and/or wrist involvement in the first 6 months was more common in those who progressed to polyarthritis.
CONCLUSION: The majority of our ANA-positive patients, including most of those who later developed polyarthritis, had monoarthritis at disease onset. Among patients with oligoarticular onset, polyarticular extension occurred in around 50% of cases within the first 3-4 years after disease onset, and tended to be less likely thereafter. The early occurrence of ankle and/or wrist disease may indicate a higher likelihood of arthritis progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142881

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Remission rate is not dependent on the presence of antinuclear antibodies in juvenile idiopathic arthritis.

Authors:  M Glerup; T Herlin; M Twilt
Journal:  Clin Rheumatol       Date:  2017-01-17       Impact factor: 2.980

2.  Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis.

Authors:  M L Stoll; P A Nigrovic; A C Gotte; M Punaro
Journal:  Clin Exp Rheumatol       Date:  2011-06-30       Impact factor: 4.473

3.  Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment.

Authors:  Estíbaliz Iglesias; Vicenç Torrente-Segarra; Rosa Bou; Silvia Ricart; María Isabel González; Judith Sánchez; Joan Calzada; Jordi Antón
Journal:  Rheumatol Int       Date:  2013-10-26       Impact factor: 2.631

4.  Circulating and synovial antibody profiling of juvenile arthritis patients by nucleic acid programmable protein arrays.

Authors:  David S Gibson; Ji Qiu; Eliseo A Mendoza; Kristi Barker; Madeleine E Rooney; Joshua LaBaer
Journal:  Arthritis Res Ther       Date:  2012-04-17       Impact factor: 5.156

5.  Predictors of response to methotrexate in juvenile idiopathic arthritis.

Authors:  Mohamed Albarouni; Ingrid Becker; Gerd Horneff
Journal:  Pediatr Rheumatol Online J       Date:  2014-08-13       Impact factor: 3.054

Review 6.  Juvenile Idiopathic Arthritis: Diagnosis and Treatment.

Authors:  Gabriella Giancane; Alessandro Consolaro; Stefano Lanni; Sergio Davì; Benedetta Schiappapietra; Angelo Ravelli
Journal:  Rheumatol Ther       Date:  2016-08-12

7.  Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization.

Authors:  Simon W M Eng; Florence A Aeschlimann; Mira van Veenendaal; Roberta A Berard; Alan M Rosenberg; Quaid Morris; Rae S M Yeung
Journal:  PLoS Med       Date:  2019-02-26       Impact factor: 11.069

8.  Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.

Authors:  Gabriella Giancane; Valentina Muratore; Valentina Marzetti; Neus Quilis; Belen Serrano Benavente; Francesca Bagnasco; Alessandra Alongi; Adele Civino; Lorenzo Quartulli; Alessandro Consolaro; Angelo Ravelli
Journal:  Arthritis Res Ther       Date:  2019-07-08       Impact factor: 5.156

Review 9.  Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis.

Authors:  Lucia M Sur; Remus Gaga; Emanuela Duca; Genel Sur; Iulia Lupan; Daniel Sur; Gabriel Samasca; Cecilia Lazea; Calin Lazar
Journal:  Life (Basel)       Date:  2021-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.